Post - marketing reevaluation of shengu granule in the treatment of senile osteoporosis.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2000003182

Enrollment

Unknown

Registered

2020-03-30

Start date

2020-04-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Senile osteoporosis

Interventions

Case series:''Sshengu granule''

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who meet the diagnostic criteria of senile osteoporosis.

Exclusion criteria

Exclusion criteria: (1) patients with chronic low back diseases (such as: osteomyelitis, bone tumor, rheumatoid arthritis, bone tuberculosis or vertebral body weight degree slippage, or patients with spinal cord caudate nerve damage, etc.); (2) patients with hyperthyroidism, hyperparathyroidism, gastrectomy, diabetes Paget's disease and other related diseases that may cause secondary osteoporosis; (3) allergic constitution or allergic to the known ingredients of the drug; (4) patients with heart, lung, liver, kidney, hematopoietic system, immune system and other serious diseases.

Design outcomes

Primary

Measure	Time frame
Dual-energy X-ray bone mineral density measurement;Biochemical indicators: electrolytes (blood calcium, phosphorus), alkaline phosphatase, etc;VAS score;Clinical symptoms and related signs of senile osteoporosis;Quality of life;	—

Countries

China

Contacts

Public ContactOuYanHua

WU HAN JUN AN pharmaceutical Co. Ltd

26075271@qq.com+86 13971067157

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026